Off-label
Use of personalized cancer drugs is getting ahead of the science
Clinical trial finds no benefit in speculative prescriptions of treatments tailored to the genetics of individual tumours.
Enthusiasm for personalized cancer drugs runs ahead of the science
Clinical trial finds no benefit in speculative prescriptions of treatments tailored to the genetics of individual tumours.
No hay comentarios:
Publicar un comentario